Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel

  • Lee, Sangmoon; 
  • Roh, Jin; 
  • Park, Jun Sung; 
  • Tuncay, Islam Oguz; 
  • Lee, Wonchul; 
  • ... Kwon, Minsuk; 
  • 외 17명
Citations

WEB OF SCIENCE

2
Citations

SCOPUS

2

초록

Purpose Cancer poses a significant global health challenge, demanding precise genomic testing for individualized treatment strategies. Targeted-panel sequencing (TPS) has improved personalized oncology but often lacks comprehensive coverage of crucial cancer alterations. Whole-genome sequencing (WGS) addresses this gap, offering extensive genomic testing. This study demonstrates the medical potential of WGS. Materials and Methods This study evaluates target-enhanced WGS (TE-WGS), a clinical-grade WGS method sequencing both cancer and matched normal tissues. Forty-nine patients with various solid cancer types underwent both TE-WGS and TruSight Oncology 500 (TSO500), one of the mainstream TPS approaches. Results TE-WGS detected all variants reported by TSO500 (100%, 498/498). A high correlation in variant allele fractions was observed between TE-WGS and TSO500 (r=0.978). Notably, 223 variants (44.8%) within the common set were discerned exclusively by TE-WGS in peripheral blood, suggesting their germline origin. Conversely, the remaining subset of 275 variants (55.2%) were not detected in peripheral blood using the TE-WGS, signifying them as bona fide somatic variants. Further, TE-WGS provided accurate copy number profiles, fusion genes, microsatellite instability, and homologous recombination deficiency scores, which were essential for clinical decision-making. Conclusion TE-WGS is a comprehensive approach in personalized oncology, matching TSO500's key biomarker detection capabilities. It uniquely identifies germline variants and genomic instability markers, offering additional clinical actions. Its adaptability and cost-effectiveness underscore its clinical utility, making TE-WGS a valuable tool in personalized cancer treatment.

키워드

Neoplasms; Biomarkers; Mutation; Precision medicine; Whole genome sequencing; MUTATIONAL SIGNATURES; CANCER; VARIANTS; BRCA1; ASSAY
제목
Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel
저자
Lee, Sangmoon; Roh, Jin; Park, Jun Sung; Tuncay, Islam Oguz; Lee, Wonchul; Kim, Jung-Ah; Oh, Brian Baek-Lok; Shin, Jong-Yeon; Lee, Jeong Seok; Ju, Young Seok; Kim, Ryul; Park, Seongyeol; Koo, Jaemo; Park, Hansol; Lim, Joonoh; Connolly-Strong, Erin; Kim, Tae-Hwan; Choi, Yong Won; Ahn, Mi Sun; Lee, Hyun Woo; Kim, Seokhwi; Kim, Jang-Hee; Kwon, Minsuk
DOI
10.4143/crt.2024.114
발행일
2025-04
유형
Article
저널명
Cancer Research and Treatment
권
57
호
2
페이지
350 ~ 361